{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:31:32Z","timestamp":1786444292169,"version":"build-2736575974"},"reference-count":50,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15760","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:17:31Z","timestamp":1783682251000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["Molecular signatures of triple\u2011negative breast cancer cells acquiring palbociclib resistance via continuous exposure"],"prefix":"10.3892","volume":"32","author":[{"given":"Daichi","family":"Enomoto","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumika","family":"Iwasa","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuho","family":"Irie","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Ohata","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Uemichi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Mabuchi","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Takara","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, Hyogo Medical University, Kobe, Hyogo 650\u20118530, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"issue":"(S3)","key":"key20260811124522_b1-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.7314\/APJCP.2016.17.S3.43","article-title":"Incidence and mortality and epidemiology of breast cancer in the world","volume":"17","author":"Ghoncheh","year":"2016","journal-title":"Asian Pac J Cancer Prev"},{"key":"key20260811124522_b2-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"469251","DOI":"10.1155\/2014\/469251","article-title":"Breast cancer survival defined by the ER\/PR\/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers","volume":"2014","author":"Parise","year":"2014","journal-title":"J Cancer Epidemiol"},{"key":"key20260811124522_b3-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260811124522_b4-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J Clin Invest"},{"key":"key20260811124522_b5-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"key20260811124522_b6-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"e02872","DOI":"10.7554\/eLife.02872","article-title":"Cyclin D activates the Rb tumor suppressor by mono-phosphorylation","volume":"3","author":"Narasimha","year":"2014","journal-title":"Elife"},{"key":"key20260811124522_b7-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1177\/1947601910392989","article-title":"Regulation of G1 cell cycle progression: Distinguishing the restriction point from a nutrient-sensing cell growth checkpoint(s)","volume":"11","author":"Foster","year":"2010","journal-title":"Genes Cancer"},{"key":"key20260811124522_b8-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1001\/jamaoncol.2015.4701","article-title":"Palbociclib (PD0332991)-a selective and potent cyclin-dependent kinase inhibitor: A review of pharmacodynamics and clinical development","volume":"2","author":"Clark","year":"2016","journal-title":"JAMA Oncol"},{"key":"key20260811124522_b9-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): A randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20260811124522_b10-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: A CDK4\/6 inhibitor for the treatment of HR+\/HER2-advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"key20260811124522_b11-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin Cancer Res"},{"key":"key20260811124522_b12-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"13014","DOI":"10.1038\/s41598-019-49484-4","article-title":"Pre-treatment with the CDK4\/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells","volume":"9","author":"Cretella","year":"2019","journal-title":"Sci Rep"},{"key":"key20260811124522_b13-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-018-0741-3","article-title":"The anti-tumor efficacy of CDK4\/6 inhibition is enhanced by the combination with PI3K\/AKT\/mTOR inhibitors through impairment of glucose metabolism in TNBC cells","volume":"37","author":"Cretella","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"key20260811124522_b14-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s10549-018-05104-9","article-title":"Synergistic anti-cancer activity of CDK4\/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer","volume":"174","author":"Yamamoto","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"key20260811124522_b15-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"100949","DOI":"10.1016\/j.neo.2023.100949","article-title":"Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy","volume":"46","author":"Winter","year":"2023","journal-title":"Neoplasia"},{"key":"key20260811124522_b16-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/nu11030624","article-title":"Baicalein suppresses stem cell-like characteristics in radio- and chemoresistant MDA-MB-231 human breast cancer cells through up-regulation of IFIT2","volume":"11","author":"Koh","year":"2019","journal-title":"Nutrients"},{"key":"key20260811124522_b17-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3390\/cancers17020228","article-title":"Triple-negative breast cancer progression and drug resistance in the context of epithelial-mesenchymal transition","volume":"17","author":"B\u0142aszczak","year":"2025","journal-title":"Cancers (Basel)"},{"key":"key20260811124522_b18-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1248\/bpb.25.771","article-title":"Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines","volume":"25","author":"Takara","year":"2002","journal-title":"Biol Pharm Bull"},{"key":"key20260811124522_b19-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.canlet.2008.12.033","article-title":"Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride","volume":"278","author":"Takara","year":"2009","journal-title":"Cancer Lett"},{"key":"key20260811124522_b20-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"4239","DOI":"10.21873\/anticanres.15228","article-title":"Induction of cross-resistance to ABCB1 substrates in venetoclax-resistant human leukemia HL60 cells","volume":"41","author":"Nakayama","year":"2021","journal-title":"Anticancer Res"},{"key":"key20260811124522_b21-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/nprot.2008.73","article-title":"Analyzing real-time PCR data by the comparative C(T) method","volume":"3","author":"Schmittgen","year":"2008","journal-title":"Nat Protoc"},{"key":"key20260811124522_b22-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"key20260811124522_b23-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"684","DOI":"10.3390\/cancers11050684","article-title":"Targeting palbociclib-resistant estrogen receptor-positive breast cancer cells via oncolytic virotherapy","volume":"11","author":"Lypova","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20260811124522_b24-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10549-021-06127-5","article-title":"Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq","volume":"186","author":"Lanceta","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"key20260811124522_b25-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"e154402","DOI":"10.1172\/jci.insight.154402","article-title":"RB expression confers sensitivity to CDK4\/6 inhibitor-mediated radiosensitization across breast cancer subtypes","volume":"7","author":"Pesch","year":"2022","journal-title":"JCI Insight"},{"key":"key20260811124522_b26-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/cas.12932","article-title":"Phase I study of palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, in Japanese patients","volume":"107","author":"Tamura","year":"2016","journal-title":"Cancer Sci"},{"key":"key20260811124522_b27-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"113198","DOI":"10.1016\/j.celrep.2023.113198","article-title":"Sequential activation of E2F via Rb degradation and c-Myc drives resistance to CDK4\/6 inhibitors in breast cancer","volume":"42","author":"Kim","year":"2023","journal-title":"Cell Rep"},{"key":"key20260811124522_b28-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/s41467-024-45796-w","article-title":"MYC induces CDK4\/6 inhibitors resistance by promoting pRB1 degradation","volume":"15","author":"Ma","year":"2024","journal-title":"Nat Commun"},{"key":"key20260811124522_b29-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.3390\/cancers12123566","article-title":"Combined CDK2 and CDK4\/6 inhibition overcomes palbociclib resistance in breast cancer by enhancing senescence","volume":"12","author":"Pandey","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20260811124522_b30-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"eadi3821","DOI":"10.1126\/sciadv.adi3821","article-title":"LncRNA EILA promotes CDK4\/6 inhibitor resistance in breast cancer by stabilizing cyclin E1 protein","volume":"9","author":"Cai","year":"2023","journal-title":"Sci Adv"},{"key":"key20260811124522_b31-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","article-title":"Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer","volume":"4","author":"Guarducci","year":"2018","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124522_b32-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1007\/s10637-015-0266-y","article-title":"P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4\/6 inhibitor palbociclib","volume":"33","author":"de Gooijer","year":"2015","journal-title":"Invest New Drugs"},{"key":"key20260811124522_b33-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.bcp.2016.10.015","article-title":"Effect of abemaciclib (LY2835219) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo","volume":"124","author":"Wu","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"key20260811124522_b34-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.phrs.2021.105954","article-title":"ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites","volume":"178","author":"Mart\u00ednez-Ch\u00e1vez","year":"2022","journal-title":"Pharmacol Res"},{"key":"key20260811124522_b35-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2174\/138161206775201965","article-title":"An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy","volume":"12","author":"Takara","year":"2006","journal-title":"Curr Pharm Des"},{"key":"key20260811124522_b36-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.biopha.2018.02.038","article-title":"Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR","volume":"100","author":"Mohammad","year":"2018","journal-title":"Biomed Pharmacother"},{"key":"key20260811124522_b37-ol-32-3-15760","first-page":"44082","article-title":"Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells","author":"Ji","year":"2019","journal-title":"Cancer Lett"},{"key":"key20260811124522_b38-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1080\/1061186X.2022.2091578","article-title":"ABC transporters in breast cancer: Their roles in multidrug resistance and beyond","volume":"30","author":"Modi","year":"2022","journal-title":"J Drug Target"},{"key":"key20260811124522_b39-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"861642","DOI":"10.3389\/fphar.2022.861642","article-title":"The resistance of cancer cells to palbociclib, a cyclin-dependent kinase 4\/6 inhibitor, is mediated by the ABCB1 transporter","volume":"13","author":"Fu","year":"2022","journal-title":"Front Pharmacol"},{"key":"key20260811124522_b40-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/cpt.2021","article-title":"Physiologically based pharmacokinetic modeling of central nervous system pharmacokinetics of CDK4\/6 inhibitors to guide selection of drug and dosing regimen for brain cancer treatment","volume":"109","author":"Li","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"key20260811124522_b41-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-022-01524-w","article-title":"CDK6-PI3K signaling axis is an efficient target for attenuating ABCB1\/P-gp mediated multi-drug resistance (MDR) in cancer cells","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol Cancer"},{"key":"key20260811124522_b42-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","article-title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance","volume":"553","author":"Zhang","year":"2018","journal-title":"Nature"},{"key":"key20260811124522_b43-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41389-023-00475-1","article-title":"CDK4\/6 inhibitors and the pRB-E2F1 axis suppress PVR and PD-L1 expression in triple-negative breast cancer","volume":"12","author":"Shrestha","year":"2023","journal-title":"Oncogenesis"},{"key":"key20260811124522_b44-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4161\/cbt.72","article-title":"Cycling to cancer with cyclin D1","volume":"1","author":"Diehl","year":"2002","journal-title":"Cancer Biol Ther"},{"key":"key20260811124522_b45-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/S1535-6108(03)00217-4","article-title":"Cell cycle progression without cyclin E\/CDK2: Breaking down the walls of dogma","volume":"4","author":"Gladden","year":"2003","journal-title":"Cancer Cell"},{"key":"key20260811124522_b46-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1158\/1078-0432.CCR-19-1425","article-title":"Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase II neoadjuvant study in HR+\/HER2\u2212breast cancer","volume":"26","author":"Hurvitz","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20260811124522_b47-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"key20260811124522_b48-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"key20260811124522_b49-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1158\/1078-0432.CCR-25-1818","article-title":"KEYLYNK-009: Pembrolizumab plus olaparib in locally recurrent inoperable or metastatic triple-negative breast cancer after clinical benefit from first-line pembrolizumab plus chemotherapy","volume":"32","author":"Rugo","year":"2026","journal-title":"Clin Cancer Res"},{"key":"key20260811124522_b50-ol-32-3-15760","doi-asserted-by":"publisher","first-page":"68012","DOI":"10.18632\/oncotarget.12010","article-title":"A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer","volume":"7","author":"Malorni","year":"2016","journal-title":"Oncotarget"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:45:26Z","timestamp":1786441526000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":50,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,10]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15760","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}